Pique Therapeutics recently announced positive results for its lead immunotherapy (PT 107) from its Phase 2 clinical trial in patients with late-stage, second-line non-small cell lung cancer (NSCLC).

These results were presented at the Society for the Immunotherapy of Cancer's 32nd Annual Meeting in National Harbor, Maryland.

    - PT 107 showed improvement in overall survival and significant     improvement in time to progression, as compared to control.

    - In non-squamous patients, the benefit of PT 107 in overall     survival was striking and highly significant.

    - PT 107 was well tolerated, with no drug-related serious adverse     events reported.


PT 107 achieved a median overall survival of 12.5 months in second-line, late stage NSCLC patients with a hazard ratio of 0.67.

In non-squamous patients, median overall survival was 15.5 months with a hazard ratio of 0.46, which was highly significant (p value of 0.0048).

PT 107 was very well tolerated with zero drug-related SAEs, consistent with previous clinical experience.

In a previous Phase 1 trial, PT 107 showed dramatic improvement in survival, with over 30% of the patients surviving more than 4 years post-treatment.

Pique Therapeutics was founded on the research of the late Eckhard R. Podack, M.D., Ph.D., who was Chair of the Department of Immunology and Microbiology at the University of Miami.